[Digestive cytomegalovirus disease in AIDS patients]. 1996

J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
Unidad de Enfermedades Infecciosas, Hospital General Vall d'Hebron, Barcelona.

BACKGROUND In this paper we study the digestive manifestations of cytomegalovirus (CMV) in AIDS patients. Also, we evaluate the antiviral treatment and the necessity of maintenance therapy. METHODS Retrospective review of medical charts of all patients with AIDS and digestive CMV disease diagnosed and followed-up since 1983 to december 1993. RESULTS Of 720 AIDS patients, 96 presented a CMV disease. Among them, 30 patients (31%) complained digestive manifestations. These were 26 males and 4 females, mean age: 37.4 y-old. Risk factors for HIV were: 13 homosex and 12 intravenous drug abusers. Average of time between AIDS diagnosis and digestive CMV disease: 13.4 months. Fourteen patients had esophagitis, 9 proctocolitis, 3 hepatitis, 3 pancreatitis, 2 gastric ulcerations, one small bowel disease and other an oral ulceration. Two patients had a concomitant CMV chorioretinitis. CD4 lymphocytes were below 0.05 x 10(9)/l in 29 patients. Twenty-four patients received antiviral treatment during the acute disease period, with a clinical curation rate of 60%. Seven patients received maintenance therapy and remained free of CMV disease until death. Eleven patients didn't received maintenance treatment. Of them, one patient presented a digestive relapse and two developed a CMV chorioretinitis. Mortality in the first month from diagnosis was 23% and the median of survival time for patients who cured and initial episode of digestive CMV disease was 208 days, wether or not the patient received maintenance therapy or not. CONCLUSIONS One third of ours patients with AIDS and CMV infection have a digestive disease. This CMV digestive disease appears in patients with a severe immunosuppression. Acute phase mortality was 23%. The median survival was 7 months, independently or receiving maintenance treatment or not.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013030 Spain Country located between France on the northeast and Portugal on the west and bordered by the Atlantic Ocean and the Mediterranean Sea. The capital is Madrid. Balearic Islands,Canary Islands

Related Publications

J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
December 1997, AIDS (London, England),
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
June 1999, Journal of chemotherapy (Florence, Italy),
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
August 1994, AIDS research and human retroviruses,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
May 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
January 1995, Scandinavian journal of infectious diseases,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
September 1997, The Annals of pharmacotherapy,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
October 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
January 1997, British journal of nursing (Mark Allen Publishing),
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
February 1992, New Jersey medicine : the journal of the Medical Society of New Jersey,
J R Barberá, and J A Capdevila, and A M García-Quintana, and I Calicó, and H Allende, and I Ruiz, and I Ocaña, and A Pahissa
August 1988, The Journal of infectious diseases,
Copied contents to your clipboard!